🇺🇸 FDA
Patent

US 12171818

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

granted A61KA61K2039/5158A61K2239/38

Quick answer

US patent 12171818 (Methods of isolating T cells having antigenic specificity for a cancer-specific mutation) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/5158, A61K2239/38, A61K39/0011, A61K40/11